Tudor Investment Corp ET AL Has $396,000 Stake in Luminex Corporation (LMNX)

Tudor Investment Corp ET AL trimmed its stake in Luminex Corporation (NASDAQ:LMNX) by 47.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,730 shares of the medical instruments supplier’s stock after selling 16,617 shares during the period. Tudor Investment Corp ET AL’s holdings in Luminex Corporation were worth $396,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Voya Investment Management LLC increased its stake in shares of Luminex Corporation by 1.9% in the 2nd quarter. Voya Investment Management LLC now owns 92,553 shares of the medical instruments supplier’s stock worth $1,955,000 after purchasing an additional 1,737 shares in the last quarter. OxFORD Asset Management LLP increased its stake in shares of Luminex Corporation by 48.6% in the 2nd quarter. OxFORD Asset Management LLP now owns 186,562 shares of the medical instruments supplier’s stock worth $3,940,000 after purchasing an additional 61,047 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Luminex Corporation by 2.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,757,980 shares of the medical instruments supplier’s stock worth $37,129,000 after purchasing an additional 39,094 shares in the last quarter. Citadel Advisors LLC increased its stake in shares of Luminex Corporation by 92.6% in the 2nd quarter. Citadel Advisors LLC now owns 235,260 shares of the medical instruments supplier’s stock worth $4,969,000 after purchasing an additional 113,139 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Luminex Corporation by 15.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,841,540 shares of the medical instruments supplier’s stock worth $38,893,000 after purchasing an additional 252,299 shares in the last quarter. Hedge funds and other institutional investors own 77.95% of the company’s stock.

Shares of Luminex Corporation (LMNX) opened at 20.79 on Friday. The stock has a market cap of $916.24 million, a price-to-earnings ratio of 64.37 and a beta of 0.29. The firm has a 50-day moving average price of $19.82 and a 200-day moving average price of $19.95. Luminex Corporation has a 52 week low of $17.64 and a 52 week high of $22.35.

Luminex Corporation (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.11. The business had revenue of $76.50 million during the quarter, compared to the consensus estimate of $75.45 million. Luminex Corporation had a net margin of 4.72% and a return on equity of 4.81%. The company’s revenue was up 19.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.33 earnings per share. On average, equities analysts anticipate that Luminex Corporation will post $0.53 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Shareholders of record on Friday, September 22nd will be given a $0.06 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.15%. Luminex Corporation’s dividend payout ratio (DPR) is currently 75.00%.

TRADEMARK VIOLATION NOTICE: This news story was posted by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2017/10/13/tudor-investment-corp-et-al-has-396000-stake-in-luminex-corporation-lmnx.html.

LMNX has been the subject of several analyst reports. Zacks Investment Research lowered Luminex Corporation from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. ValuEngine lowered Luminex Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, July 8th. BidaskClub lowered Luminex Corporation from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, TheStreet lowered Luminex Corporation from a “b” rating to a “c+” rating in a research note on Monday, August 7th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $20.00.

In other Luminex Corporation news, Director Robert J. Cresci sold 19,631 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $18.98, for a total value of $372,596.38. Following the completion of the transaction, the director now owns 260,358 shares in the company, valued at $4,941,594.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Luminex Corporation Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)

Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply